Physician profile
Ramanakumar Anam
NPI 1144889973
$4,028.90
in general payments reported to CMS, 2019-2025
21 companies · $2,073 in 2025
The $2,073 reported for 2025 was more than what 89% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2022: $82.49 · 2023: $661 · 2024: $1,028 · 2025: $2,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,612 · Travel and Lodging: $1,012 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,612.18 |
| Travel and Lodging | $1,012.27 |
| Education | $137.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mozarc Medical US LLC | $1,183.26 | 2025 | Argyle |
| Travere Therapeutics, INC. | $505.28 | 2022-2025 | Filspari |
| Astrazeneca Pharmaceuticals LP | $483.25 | 2023-2025 | Lokelma, Farxiga |
| Calliditas Therapeutics US INC. | $208.50 | 2023-2025 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $204.06 | 2023-2025 | Ultomiris, Soliris |
| Novartis Pharmaceuticals Corporation | $173.83 | 2024-2025 | |
| Medtronic, INC. | $157.69 | 2023-2024 | In.Pact Av, In.Pact Admiral |
| Penumbra, INC. | $137.40 | 2025 | Penumbra System |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $128.51 | 2023-2024 | |
| Amgen INC. | $126.86 | 2025 | Tavneos |
| Edwards Lifesciences Corporation | $119.94 | 2019 | |
| Mallinckrodt Hospital Products INC. | $107.53 | 2024-2025 | Terlivaz, Acthar |
| Otsuka America Pharmaceutical, INC. | $106.26 | 2024-2025 | Jynarque |
| Lilly USA, LLC | $64.74 | 2019 | |
| Opko Pharmaceuticals, LLC | $63.63 | 2023-2025 | Rayaldee |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $58.78 | 2023-2024 | Nxstage System One, Liberty Select Cycler |
| Daiichi Sankyo INC. | $53.99 | 2023-2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $53.26 | 2022 | |
| Vifor Pharma, INC. | $45.80 | 2023 | Veltassa |
| Aurinia Pharma U.S., INC. | $23.22 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.11 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramanakumar Anam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.